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 Reporting Guidelines for Clinical Trials Evaluating Artificial Intelligence 
Interventions are Needed 
As artificial intelligence moves into the realm of clinical trials, 
consideration is needed on whether the current CONSORT and SPIRIT 
reporting statements are sufficient to ensure transparency. 
The CONSORT-AI and SPIRIT-AI Steering Group 
As of June 2019, more than 30 AI algorithms have been approved by the US Food and Drug 
Administration (including for the detection of diabetic retinopathy, stroke, brain haemorrhage, 
atrial fibrillation)1 and over 300 clinical trials have been registered on ClinicalTrials.gov under the 
headings ‘artificial intelligence’, ‘machine learning’ or ‘deep learning’. These algorithms have the 
potential to transform healthcare, by offering earlier and more accurate diagnoses, lending novel 
insights into our understanding of diseases, enabling faster and more efficient service delivery 
and making medical care more available to those who really need it.  Optimal reporting is key for 
evaluating the clinical utility of algorithms, for informing health policy and evidence-based 
recommendation, and to prevent research waste.2 Most AI-interventions thus far, particularly 
diagnostic algorithms, have only been evaluated in the context of diagnostic accuracy. Whilst this 
initial validation stage is important, a demonstration of good diagnostic accuracy does not 
necessarily translate to improved patient outcomes. If the ultimate goal of introducing AI into 
healthcare is to bring about patient benefit, then demonstration of improved patient outcome is 
needed.  This should be done in a prospective clinical trial, where the AI intervention is placed 
within its intended clinical pathway, with patient outcomes as the primary endpoint, and with 
demonstrable downstream effects in the broader management strategy. 
 The CONSORT (Consolidated Standards of Reporting Trials)3 and SPIRIT (Standard Protocol 
Items: Recommendations for Interventional Trials)4 statements are minimum reporting guidelines 
for randomised trials and trial protocols. Their widespread endorsement has been instrumental in 
ensuring transparency and completeness for the evaluation of new interventions. 
Although this guidance has substantially improved the completeness of clinical trials reporting, 
there are challenges in trials involving AI interventions that are not addressed by the current 
guidance. For example, elements which require detailed and specific reporting include the study 
setting and its ability to administer an ML intervention in real time, the criteria for inclusion at the 
input-data level as well as at the participant level, the interactions between the human and the 
algorithm and its potential knock-on effects downstream, and adaptive machine learning 
technologies (which have the potential to continuously improve in performance). Without complete 
and transparent reporting, readers cannot assess the validity and generalisability of the findings, 
which can result in widespread misconception of overstated efficacy and utility. The risk is that an 
AI-intervention, which might not be effective or feasible in the real world, could be commissioned 
and implemented.  
To address these challenges, the CONSORT-AI and SPIRIT-AI Working Group is preparing  
international, consensus-based, AI-specific extensions to the CONSORT and SPIRIT statements 
that will specifically focus on clinical trials in which the intervention includes an ML or other AI 
component, using the Enhancing Quality and Transparency of Health Research’s (EQUATOR) 
Network methodological framework for guideline development. This initiative will be 
complementary to the efforts of others working on reporting standards such as the TRIPOD-ML 
initiative of Collins and Moons, which seeks to improve reporting of ML-driven predictive models 
development and validation.6 Our development process includes clinicians, computer scientists, 
researchers, trialists, industry leaders, regulators, funders, policy makers, journal editors and 
patient partners with an interest in applications of machine learning in healthcare. Through strong 
 stakeholder engagement and a modified Delphi consensus process, the AI extensions for 
CONSORT and SPIRIT guidelines will adequately reflect the concerns of the wider community.   
Although many voices are important in this field, we wish to particularly draw attention to the role 
of medical journal editors. The endorsement of reporting standards by medical journals has been 
instrumental in ensuring that new interventions are reported transparently and completely to 
improve decision-making in healthcare. As seen with the original CONSORT and SPIRIT 
guidelines, the real impact depends on the extent to which journals adopt and require authors to 
comply with these standards. We wish to acknowledge the profound impact that the ICMJE 
(International Committee of Medical Journal Editors) community had on the quality of RCT 
reporting through their adoption of CONSORT. We strongly encourage the community of medical 
journal editors, particularly those with a focus on digital health, to take part in the Delphi process 
and support the endorsement of the final guidance in future publications. 
A final consensus meeting and the publication of final recommendations will be completed in 
Spring 2020. Once the new guidance becomes available, we recommend that investigators 
planning to take an AI intervention through to clinical trials consult the new reporting standards 
as early as possible. Whilst the guidance will primarily be for ensuring reporting transparency, 
they can also assist in clinical trial design.  
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